A third kidney transplant: Cost-effective treatment for end-stage renal disease?

Clinical Transplantation

Volumn 10, Issue 6 I, 1996, Pages 516-520

  Matas, Arthur J ^a,b   Gillingham, Kristen J ^a   Payne, William D ^a   Dunn, David L ^a   Gruessner, Rainer W G ^a   Sutherland, David E R ^a   Schmidt, Walter ^a   Najarian, John S ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cost effectiveness; Kidney transplantation

Indexed keywords

ADULT; ARTICLE; CADAVER DONOR; COST EFFECTIVENESS ANALYSIS; FEMALE; GRAFT SURVIVAL; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADOLESCENT; ADULT; CADAVER; COST-BENEFIT ANALYSIS; EMPLOYMENT; FEMALE; FOLLOW-UP STUDIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT SURVIVAL; HEMOLYTIC-UREMIC SYNDROME; HOSPITAL CHARGES; HOSPITAL COSTS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; PATIENT READMISSION; PATIENT SELECTION; QUALITY OF LIFE; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030480908     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. The UNOS Statement of Principles and Objectives of Equitable Organ Allocation. UNOS Update. Vol. 10, Issue 8, August 1994.
2. EVANS RW. A cost-outcome analysis of retransplantation: The need for accountability. Transpl Rev 1993: 7: 163.
3. ALMOND PS, MATAS AJ, GILLINGHAM K, et al. Risk factors for second renal allografts immunosuppressed with cyclosporine. Transplantation 1991: 52: 253.
4. KAHAN BD, MICHEY R, FLECHNER SM, et al. Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Transplantation 1987: 43: 65.
5. STRATA RJ, CHOONG-SAN O, SOLLINGER HW, et al. Kidney transplantation in the cyclosporine era. Transplantation 1988: 45: 40.
6. FRYER JP, MATAS AJ. How to identify the best candidates for kidney transplantation. Protocols for making the best use of scarce donor organs. J Crit Illness 1994: 9: 362.
7. JONES JW, PAYNE WD, MATAS AJ: The living donor: risks, benefits, and related concerns. Transpl Rev 1993: 7: 115.
8. MATAS AJ, GILLINGHAM KJ, SUTHERLAND DER. Half-life and risk factors for kidney transplant outcome: importance of death with function. Transplantation 1993: 55: 757.
9. GEHAN EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965: 52: 203.
10. STEPHANIAN E, MATAS AJ, GORES P, SUTHERLAND DER, NAJARIAN JS. Retransplantation as a risk factor for lymphocele formation. Transplantation 1992: 53: 676.
11. STEPHANIAN E, MATAS AJ, MAUER SM, et al. Recurrence of disease in patients retransplanted for focal segmental glomerulosclerosis. Transplantation 1992: 53: 755.